Loading...

The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance

Vascular endothelial growth factor (VEGF) has become a major target in cancer treatment as it promotes tumor angiogenesis. Therapy with anti-VEGF antibody bevacizumab reportedly induces high levels of circulating VEGF which may potentially contribute to resistance. Based on animal or computational m...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncotarget
Main Authors: Alidzanovic, Lejla, Starlinger, Patrick, Schauer, Dominic, Maier, Thomas, Feldman, Alexandra, Buchberger, Elisabeth, Stift, Judith, Koeck, Ulrike, Pop, Lorand, Gruenberger, Birgit, Gruenberger, Thomas, Brostjan, Christine
Format: Artigo
Sprog:Inglês
Udgivet: Impact Journals LLC 2016
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5302983/
https://ncbi.nlm.nih.gov/pubmed/27527865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11084
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!